Pfizer signs $1.25bn cancer antibody licensing deal with China's 3SBio

The US giant will pay the money upfront for distribution rights for SSGJ-707 outside of China; the deal could be worth up to $4.8bn and Pfizer will also invest $100m into the HKEX listed firm.

Andrew Tjaardstra

May 21, 2025

Pfizer has entered into an exclusive global, ex-China, licensing agreement with 3SBio a Chinese biopharmaceutical company, listed on the Hong Kong Stock Exchange (HKEX), according to a May 19 company announcement.

Sign in to read on!

Registered users get 2 free articles in 30 days.

Subscribers have full unlimited access to FinanceAsia.

Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.

Questions?
See here for more information on licences and prices, or contact [email protected].

Markets
Equity
North Asia
Rest Of World

#pfizer
#2sbio
#pharmaceutical